{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:36Z","timestamp":1780031136294,"version":"3.53.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Background<\/jats:title>\n Prostate cancer is the most commonly diagnosed oncological disease among men not only in Russia but also worldwide, while meningioma is the one of the most commonly diagnosed primary central nervous system (CNS) intracranial tumor. However, their combination occurs quite rarely. Prostate-specific membrane antigen radioligand therapy (PSMA RLT) might be an extremely perspective treatment option for these patients as both neoplasms are characterized by PSMA expression.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n After PET\/CT demonstrated a high [\n 68<\/jats:sup>\n Ga]\n 68<\/jats:sup>\n Ga-PSMA-11 uptake level in metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma in a 77-year old patient, we performed four administrations of [\n 225<\/jats:sup>\n Ac]Ac-PSMA-617. evaluating the prostate-specific antigen (PSA) dynamics and the structural response by brain MRI and PET\/CT with [\n 68<\/jats:sup>\n Ga]Ga-PSMA-11. In addition, we evaluated the patient\u2019s complaints and his hematological indications.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n After treatment, the patient revealed a remarkable decrease in the [\n 68<\/jats:sup>\n Ga]Ga-PSMA-11 uptake level based on the PET\/CT data, a decrease in the PSA level by 99.8%, and a decrease in the meningioma size by 90.6%. Among the unfavorable symptoms, high-grade xerostomia (CTCAE v5.0) was revealed. The hematological parameters remained stable for the whole period of observation.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The presented clinical case report describes a unique positive experience on the use of [\n 225<\/jats:sup>\n Ac]Ac-PSMA-617 therapy in mCRPC and brain meningioma, thus allowing us to expand our understanding of PSMA RLT as a method for the treatment of not only prostatic tumors but also tumors of non-prostatic locations.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1803812","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:57:06Z","timestamp":1780030626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma"],"prefix":"10.3389","volume":"16","author":[{"given":"Iskander","family":"Musabaev","sequence":"first","affiliation":[{"name":"National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation","place":["Obninsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Goryaynov","sequence":"additional","affiliation":[{"name":"National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation","place":["Obninsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Yu Kochetova","sequence":"additional","affiliation":[{"name":"National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation","place":["Obninsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerii","family":"Krylov","sequence":"additional","affiliation":[{"name":"National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation","place":["Obninsk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Ivanov","sequence":"additional","affiliation":[{"name":"National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation","place":["Obninsk, Russia"]},{"name":"Department of Urology and Operative Nephrology, Peoples' Friendship University of Russia (RUDN University)","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","volume-title":"Zlokachestvennye novoobrazovaniia v Rossii v 2023 godu. Zabolevaemost\u2019 i smertnost\u2019 (Malignant neoplasms in Russia in 2023. Morbidity and mortality)","author":"Kaprin","year":"2024"},{"key":"B2","first-page":"10","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268781","article-title":"Consensus nomenclature for radionuclide therapy: Initial recommendations from nuclear medicine global initiative","volume":"66","author":"Al-Ibraheem","year":"2025","journal-title":"J Nucl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"225Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med"},{"key":"B7","article-title":"Spasitel\u2019naia terapiia 225Ac-PSMA pri metastaticheskom kast ratsionno-rezistentnom rake predstatel\u2019noi zhelezy v tret\u2019ei linii radionuklidnoi terapii u patsienta s anemies i trombotsitopeniei (Salvage therapy with 225Ac-PSMA for metastatic castration-resistant prostate cancer in the third line of radionuclide therapy in a patient with anemia and thrombocytopenia)","volume":"7","author":"Kochetova","year":"2024","journal-title":"Onkologicheskii zhurnal: luchevaia diagnostika luchevaia terapiia"},{"key":"B8","unstructured":"Diagnosis of renal cell carcinoma on 68Ga-PSMA PET-CT and radioligand therapy with 177Lu-EB-PSMA-617\n \n \n \n 2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.WJNM_112_18","article-title":"177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment","volume":"18","author":"Assadi","year":"2019","journal-title":"World J Nucl Med"},{"key":"B10","unstructured":"Lutetium-177-PSMA radioligand therapy for advanced salivary gland cancer, a phase II pilot study\n \n \n \n 2023"},{"key":"B11","article-title":"Otdalennye rezul\u2019taty khirurgicheskogo lecheniia parasagittal\u2019nykh meningiom golovnogo mozga (Long-term results of surgical treatment of parasagittal meningiomas of the brain)","author":"Stupak","year":"2015","journal-title":"Sovremennye problemy nauki i obrazovaniia"},{"key":"B12","first-page":"555","volume-title":"Vnutri-cherepnye menigiomy (Intracranial meningiomas)","author":"Tigliev","year":"2001"},{"key":"B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.17116\/neiro201780774-80","article-title":"Early postoperative results of surgical treatment of patients with anterior clinoidal meningiomas","volume":"81","author":"Chernov","year":"2017","journal-title":"Burdenko J Neurosurg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-008-9734-y","article-title":"Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas","volume":"92","author":"Sioka","year":"2009","journal-title":"J Neuro-Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlac089","article-title":"Prostate-specific membrane antigen expression in meningioma: A promising theranostic target","volume":"81","author":"Teddi","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.37174\/2587-7593-2024-7-1-30-40","article-title":"Pilotnoe issledovanie bezopasnosti trekh vozrastaiushchikh aktivnostei 225Ac-PSMA dlia lecheniia metastaticheskogo kast ratsionno-rezistentnogo raka predstatel\u2019noi zhelezy (Pilot study of the safety of three escalating activities of 225Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer)","volume":"7","author":"Kochetova","year":"2024","journal-title":"Onkologicheskii zhurnal: luchevaia diagnostika luchevaia terapiia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21294\/1814-4861-2024-23-6-32-40","article-title":"Rezultaty terapii 225Ac-PSMA-617 bol\u2019nykh metastaticheskim kaastratsionno-rezistentnym rakom predstatel\u2019noi zhelezy (Results of 225Ac-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer)","volume":"23","author":"Kochetova","year":"2024","journal-title":"Sibirskii onkologicheskii zhurnal"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2021.08.014","article-title":"Incidental prostate-specific membrane antigen-avid meningioma detected on 68Ga\u2013prostate-specific membrane antigen PET\/CT","volume":"16","author":"Jiang","year":"2021","journal-title":"Radiol Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/20584601241240318","article-title":"Intense prostate-specific membrane antigen receptor expression in coronary artery bypass graft scar tissue: a potential molecular imaging pitfall","volume":"13","author":"Al-Ibraheem","year":"2024","journal-title":"Acta Radiol Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07168-4","article-title":"Evaluating xerostomia as a side effect of [255Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis","volume":"52","author":"Al-Ibraheem","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1220586","article-title":"PSMA-targeted therapy for non-prostate cancers","volume":"13","author":"Wakabayashi","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:57:08Z","timestamp":1780030628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1803812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1803812"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1803812","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1803812"}}